Arcturus Therapeutics Holdings Inc. (ARCT)
ARCT Stock Price Chart
Explore Arcturus Therapeutics Holdings Inc. interactive price chart. Choose custom timeframes to analyze ARCT price movements and trends.
ARCT Company Profile
Discover essential business fundamentals and corporate details for Arcturus Therapeutics Holdings Inc. (ARCT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
22 May 2013
Employees
174.00
Website
https://arcturusrx.comCEO
Joseph E. Payne
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
ARCT Financial Timeline
Browse a chronological timeline of Arcturus Therapeutics Holdings Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$1.09, while revenue estimate is $17.47M.
Earnings released on 11 Aug 2025
EPS came in at -$0.34 surpassing the estimated -$1.11 by +69.37%, while revenue for the quarter reached $28.30M , beating expectations by +54.29%.
Earnings released on 12 May 2025
EPS came in at -$0.52 surpassing the estimated -$1.58 by +67.09%, while revenue for the quarter reached $29.38M , beating expectations by +25.84%.
Earnings released on 6 Mar 2025
EPS came in at -$1.11 falling short of the estimated -$0.33 by -236.36%, while revenue for the quarter reached $21.00M , missing expectations by -52.96%.
Earnings released on 7 Nov 2024
EPS came in at -$0.26 surpassing the estimated -$0.70 by +62.86%, while revenue for the quarter reached $38.82M , missing expectations by -15.48%.
Earnings released on 5 Aug 2024
EPS came in at -$0.64 surpassing the estimated -$1.85 by +65.41%, while revenue for the quarter reached $45.98M , beating expectations by +34.24%.
Earnings released on 8 May 2024
EPS came in at -$1.00 surpassing the estimated -$1.17 by +14.53%, while revenue for the quarter reached $32.60M , beating expectations by +85.85%.
Earnings released on 7 Mar 2024
EPS came in at -$0.32 surpassing the estimated -$1.69 by +81.07%, while revenue for the quarter reached $28.21M , missing expectations by -25.48%.
Earnings released on 14 Nov 2023
EPS came in at -$0.61 surpassing the estimated -$1.79 by +65.92%, while revenue for the quarter reached $43.38M , beating expectations by +4.17%.
Earnings released on 7 Aug 2023
EPS came in at -$1.98 falling short of the estimated $0.09 by -2.30K%, while revenue for the quarter reached $9.57M , missing expectations by -80.28%.
Earnings released on 9 May 2023
EPS came in at $0.88 falling short of the estimated $2.92 by -69.86%, while revenue for the quarter reached $79.73M , beating expectations by +110.14%.
Earnings released on 28 Mar 2023
EPS came in at $4.43 surpassing the estimated $0.98 by +352.04%, while revenue for the quarter reached $160.05M , beating expectations by +120.21%.
Earnings released on 9 Nov 2022
EPS came in at -$1.33 surpassing the estimated -$2.01 by +33.83%, while revenue for the quarter reached $13.37M , beating expectations by +192.86%.
Earnings released on 9 Aug 2022
EPS came in at -$0.82 surpassing the estimated -$1.84 by +55.43%, while revenue for the quarter reached $27.09M , beating expectations by +763.69%.
Earnings released on 9 May 2022
EPS came in at -$1.94 falling short of the estimated -$1.29 by -50.39%, while revenue for the quarter reached $5.24M , missing expectations by -25.96%.
Earnings released on 28 Feb 2022
EPS came in at -$1.47 surpassing the estimated -$1.77 by +16.95%, while revenue for the quarter reached $5.79M , missing expectations by -60.72%.
Earnings released on 8 Nov 2021
EPS came in at -$2.05 falling short of the estimated -$1.40 by -46.43%, while revenue for the quarter reached $2.44M , missing expectations by -79.08%.
Earnings released on 9 Aug 2021
EPS came in at -$2.07 falling short of the estimated -$1.99 by -4.02%, while revenue for the quarter reached $2.00M , meeting expectations.
Earnings released on 10 May 2021
EPS came in at -$2.15 falling short of the estimated -$1.16 by -85.34%, while revenue for the quarter reached $2.13M , beating expectations by +44.30%.
Earnings released on 1 Mar 2021
EPS came in at -$1.25 falling short of the estimated -$0.90 by -38.89%, while revenue for the quarter reached $2.24M .
Earnings released on 9 Nov 2020
EPS came in at -$0.92 falling short of the estimated -$0.47 by -95.74%, while revenue for the quarter reached $2.33M , beating expectations by +46.65%.
ARCT Stock Performance
Access detailed ARCT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.